Astellas Nabs Class-first FDA Approval for CLDN18.2 Gastric Cancer Med Vyloy
After a prior rejection, Astellas receive a class-first FDA approval for its new gastric cancer med Vyloy.
The FDA gave Vyloy (zolbetuximab) the thumbs-up as a fi...